Background: Allergen-specific immunotherapy can induce long-term suppression of
| INTRODUCTION
Allergen-specific immunotherapy (SIT) has been used for the treatment of allergic disorders for over a century. 1 Specific immunotherapy (SIT) has been shown to induce durable immunological changes in response to the allergen, through generating neutralizing antibodies, through suppressing numbers and activity of allergen-specific Th2 cells and type 2 innate lymphoid cells (ILC2s), and by inducing regulatory T-cell activity. 2 Successful SIT has been associated with enhanced release of IL-10 in PBMC cultures restimulated with allergen, 3 serum-dependent suppression of cross-presentation by B cells, 4 and selective loss of those T-cell clones with allergen-epitope specificities that are increased in atopic individuals compared to healthy controls. 5, 6 Specific immunotherapy (SIT) induces long-term tolerance to the allergen, as evidenced by the absence of allergic manifestations upon repeated allergen challenges. which might interfere with the tolerance-inducing capacity required for successful therapy. 7 In contrast, use of purified proteins allows for treatment with specific allergens in the absence of such components contained within extracts. 8 This is expected to enhance SIT efficacy by more efficiently inducing a tolerogenic response due to the absence of TLR agonists during allergen administration, harnessing an immunoregulatory phenotype of the allergen-presenting cell upon SCIT. 1 Moreover, use of purified allergens in combination with a component-resolved diagnosis of sensibilization patterns holds the promise of personalized intervention strategies in immunotherapy. 8 However, it is currently unknown whether purified allergens are a more efficient treatment modality than full allergen extracts.
House dust mite (HDM) is the most prominent source of indoor exposure to allergens and is a cause for allergic rhinitis and asthma. 9 The HDM species Dermatophagoides pteronyssinus (Der p) has at least 23 major allergens 9 that are thought to contribute to allergic sensitization through their proteolytic activity, activating cells of the innate immune system and priming an adaptive type 2 immune response. 2, 9 In the MAS prospective birth cohort, sensitization patterns for HDM allergens were studied into detail by component-resolved analysis. 10 Herein, specific IgE (spIgE) for Der p1, 2, and 23 can be detected before sensitization to any of the other major allergens. Moreover, sensitization to Der p1, 2, and 23 allergens has the highest prevalence, with more than half of the 20-year-old individuals having spIgE to group 1 and 2 allergens. 10 Interestingly, early onset of sensitization to group 1, 2, or 23 allergens was associated with sensitization to more HDM allergens and with allergic rhinitis and asthma at school age, indicating the clinical relevance of these sensitization patterns. 10 Treatment options for HDM allergy include allergen avoidance and SIT. 11 However, HDM extracts are variable in content of allergens, 12, 13 and stability is limited. 14 Given the fact that sensitization to Der p1 and 2 identifies more than 95% of HDM-allergic individuals 9, 13 and their causal role in early sensitization, 10 SIT with purified Der p1 and 2 might be a more attractive therapeutic approach compared to the use of HDM extracts.
Here, we test the hypothesis that treatment with natural purified Der p1 and 2 is an effective treatment in inducing a protective neutralizing antibody response and in suppressing allergic inflammation in a mouse model of HDM-driven allergic asthma. We find that SCIT with a mixture of Der p1 and 2 is superior to extract in suppressing from Der p was performed by ion exchange and size exclusion chromatography as previously described. [15] [16] [17] [18] Purified proteins were separated by SDS-PAGE to evaluate purity and stability ( Figure 1 ).
| Experimental animals
BALB/cByJ mice were purchased from Charles River Laboratories (L'Arbresle, France) at an age of 6 to 8 weeks and housed in individually ventilated cages (IVC). Animal housing and experiments were performed in accordance with the guidelines of and after written approval by the Institutional Animal Care and Use Committee at the University of Groningen. All groups consisted of eight female mice.
| Allergic asthma treatment protocol
All mice received injections of 5 lg crude extract HDM adsorbed to 2.25 mg Alum (Imject, Pierce) in 100 lL PBS (Figure 2A ). Subcutaneous immunotherapy (SCIT) was performed by three injections on alternate days, 19 using 250 lg crude extract HDM, or naturally purified Der p1 and 2 in a 50/1 ratio (100 lg DerP1/2), applied either in 100 lL PBS or as freshly prepared emulsions of the purified | 863
| Ear swelling response (ESR)
Before and after SCIT treatment, an ear swelling test (EST) was performed to evaluate the early-phase response to HDM to test for allergic sensitization, as previously described. 
| Bronchoalveolar lavage fluid (BALF)
Lungs were lavaged, and cytospin preparations were made according to previous published protocols. 19 2.7 | T-cell responses: restimulation of lung cells B, Outline of the treatment groups. C, House dust mite (HDM) specific IgG1, Der p1 specific IgG1, and Der p2 specific IgG1 levels measured in sera taken after SCIT and after challenges (arbitrary units (AU)/mL, post-SCIT and postchallenges). D, House dust mite (HDM)-spIgG2a, Der p1-spIgG2a, and Der p2-spIgG2a levels measured in sera taken before and after challenges (AU/mL, post-SCIT and postchallenges). E, House dust mite (HDM)-spIgE, Der p1-spIgE, and Der p2-spIgE levels measured in sera taken before and after challenges (AU/mL, post-SCIT and postchallenges). F, Total IgE (ng/mL) levels measured in sera taken before and after challenges (ng/mL, post-SCIT and postchallenges), and the neutralizing activity plotted as ratio of Der p1-spIgG1/Der p1-spIgE levels in post-SCIT-sera (middle) and post-challenge-sera (right). In Figure 1C -F, values are expressed as mean AE SEM (n = 8). The neutralizing activities in Figure 1F are expressed in the box-and-whisker plots (min-max). *P < .05, **P < .01, and ***P < .001 compared to PC at the same time point. NC: Negative control, PBS challenged; PC: positive control, HDM challenged; HDM and DerP1/2: different SCIT-treated mice, HDM challenged concentrations of IL-5, IL-10, IL-13 and IFN-c, according to the manufacturer's instructions (BD Pharmingen, CA).
| Analysis of cytokine levels in lung tissue
The right superior lobe was used for measurement of total protein, and concentrations of IL-4, IL-5, IL-10, IL-13, IL-17, IL-33, IFN-c, eotaxin/CCL11, TARC/CCL17, and MIP3-a/CCL20
were measured using a MILLIPLEX Map Kit (Merck Millipore
Corp., Germany) and analyzed according to the manufacturer's protocol.
| HDM and Der p1 and Der p2 specific Immunoglobulins
Blood was collected at several time points in the experiment (preand postserum). House dust mite (HDM)-spIgE, Der p1-spIgE and p2-spIgE, Der p1-spIgG1, and Der p1-spIgG2a levels were measured by ELISA in a similar protocol as described previously 7 and in Table S1 .
| Statistical analyses
All data are expressed as mean AE SEM. The Mann-Whitney U test was used to analyze the results, and P < .05 was considered significant. Within the AHR measurements, a generalized estimated equation (GEE) analysis was used, using SPSS Statistics 20.0.0.2.
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Nonparametric Spearman's correlations were performed in Figure 5D ,E.
See additional methods descriptions in the online supplemental methods.
3 | RESULTS
| Preparation, stability, and purity of natural Der p1 and Der p2
To establish a purified DerP1/2 vaccine, we optimized biochemical purification from aqueous extracts of whole mite cultures and analyzed protein stability ( Figure 1A ). Both Der p1 and 2 are stable for prolonged period of time, with minor loss of protein intensity after 46 hours of incubation at 37°C. Analysis of Der p1 revealed the presence of smaller fragments, sized 25 kDa (a), 17 kDa (b), and 14 kDa (c, Figure 1B ). These fragments correspond to Der p1 breakdown products given the endogenous cysteine protease activity of Der p1. 11, 12 Maldi-TOF analysis on these fragments confirmed their identity as Der p1 peptides ( Figure 1B ). Using these Der p1 and 2 batches, we generated a DerP1/2 vaccine by mixing in a 50:1 w/w ratio.
| DerP1/2-SCIT enhances HDM-spIgG2a levels
Next, we aimed to test whether purified Der p1 and 2 proteins
showed clinical efficacy in our SIT model. House dust mite (HDM)-sensitized mice received SCIT with DerP1/2 or HDM, or PBS control, followed by HDM challenges to evaluate whether the allergic response is suppressed by SCIT (Figure 2A,B) . As SCIT induces a neutralizing antibody response, 1 we evaluated spIgG1, and spIgG2a
after SCIT (post-SCIT) and after challenges (postchallenge, Figure 2C , D). SCIT with either DerP1/2 or HDM did not affect HDM-spIgG1 levels after treatment, or at the time of challenges. In contrast, only DerP1/2-SCIT was able to induce a significantly increased HDMspIgG2a response, at both time points.
3.3 | DerP1/2 and HDM-SCIT enhance Der p1-spIgG1 and Der p1-spIgG2a
As we used purified Der p1 and 2, we also analyzed Der p1 and 2 specific immunoglobulins. Here, we observed increased Der p1-spIgG1 levels after DerP1/2-SCIT ( Figure 2C ). Subsequent challenges resulted in increased Der p1-spIgG1 levels in both HDM-SCIT and DerP1/2-SCIT groups.
For Der p1-spIgG2a, we observed a significant increase after DerP1/2-SCIT; while in the HDM-SCIT group, increased Der p2-spIgG2a levels were only detected after allergen challenges (Figure 2D ). Der p2-spIgG1 or Der p2-spIgG2a responses were not observed in any of the groups.
| Specific IgE responses after DerP1/2-SCIT and HDM-SCIT
Remarkably, most of the positive controls failed to induce a sufficiently high IgE response, visualized in the total IgE and HDM-spIgE levels plotted in Figure 2E ,F. Therefore, when both HDM-SCIT and DerP1/2-SCIT groups were compared to these positive controls, we found significant increases at both time points. Also, levels of Der p1-spIgE and 2-spIgE were significantly increased after both HDM and DerP1/2-SCIT compared to controls ( Figure S1A ).
Clinical efficacy of SIT is associated with the neutralizing capacity of the spIgGs, 4 while symptom score in allergic asthma is inversely correlated to the ratio of spIgG over spIgE, 22 indicating the relevance of IgG response induced during SIT. Therefore, we calculated the changes in the ratio of Der p1-spIgG1 over Der p1-spIgE and compared between groups ( Figure 2F ). We find significantly increased spIgG/spIgE ratios both before and after challenges with DerP1/2-SCIT compared to positive controls. House dust mite (HDM)-SCIT mice, however, only display an increased IgG/IgE ratio after HDM challenges, but not after SCIT. A complete overview of all ratios is plotted in Figure S1B . These analyses reveal that Der p1-spIgG1 is the main isotype of neutralizing antibodies induced by SCIT in our experiment. . Absolute values are expressed as mean AE SEM (n = 8). *P < .05, **P < .01, and ***P < .001 compared to PC. NC: Negative control, PBS challenged; PC: positive control, HDM challenged; HDM and DerP1/2: different SCIT treatments, HDM challenged Figure 3B ). Herein, both HDM-SCIT and DerP1/2-SCIT show a trend toward increased ED3 compared to the positive controls. Next, we compared the resistance across all dose-response curves and found that both HDM-SCIT and DerP1/2-SCIT were significantly reduced, as evidenced from a right shift of curves and a reduced plateau at higher concentrations ( Figure 3C ). In addition, while we observed significantly Concentrations were calculated as the concentration after restimulation minus control and plotted in the box-and-whisker plots (min-max). *P < .05, **P < .01, and ***P < .001 compared to PC. NC: Negative control, PBS challenged; PC: positive control, HDM challenged; HDM and DerP1/2: different SCIT treatments, HDM challenged reduced compliance in HDM-challenged mice, both HDM-SCIT and DerP1/2-SCIT did not improve lung compliance ( Figure 3D ). Figure 5B ). We also measured IFN-c levels to control for any effect on Th1 cell activity and found no induction in this model.
| DerP1/2-SCIT suppresses release of the epithelial chemokine CCL20
To test whether SCIT also affected the innate response to allergens,
we assessed levels of pro-inflammatory chemokines and alarmins released by lung structural cells upon HDM exposure. 7 Here, we observe that challenges clearly induced release of eotaxin, IL-33, TARC/CCL17, and MIP3a/CCL20 indicating activation of the innate immune system and structural cells ( Figure 5B,C) . Interestingly, we observed that only DerP1/2-SCIT resulted in suppression of CCL20 levels and showed a trend toward suppression of eotaxin, IL-33, and CCL17 levels in lung tissue. No significant effect of SCIT on IL-17 was observed (data not shown).
Next, we asked whether the levels of the Der P1 specific neutralizing antibodies after SCIT correlated with a decreased AHR or immunological response after HDM challenges. Here, we found a negative correlation between Der p1-spIgG1 (post-SCIT) vs the lung cytokines IL-4, IL-5, and CCL20 and BALF IL-5 levels ( Figure 5D ,E).
In contrast, we did not observe a significant correlation between the Der p1-spIgG1 levels and the more translational parameters ED3 or the EST. Figure 6A ,B). 23 We find that low DerP1/2 dosages do not suppress ESR after challenge. In contrast, the highest dose of the DerP1/2-SCIT groups did induce significant suppression compared to SAINT-treated controls ( Figure 6C ). In addition, the DerP1/2 vaccine dose dependently modified eosinophilic inflammation and AHR ( Figure 6D ,E). Remarkably, low-dose DerP1/2 exaggerated eosinophilic inflammation and AHR.
In contrast, 20 lg DerP1/2 did show therapeutic effect, albeit limited, in suppressing AHR, while airway eosinophilia was not suppressed. All three doses of DerP1/2 failed to suppress IL-4, IL-5, and IL-17 levels in lung tissue. Furthermore, only the highest dose of DerP1/2 was able to suppress IL-33 ( Figure 6F ).
Overall, while the lowest dose of the DerP1/2 vaccine exaggerated the allergic phenotype, the use of 20 lg was capable of suppressing some of the allergic asthma parameters, such as AHR and lung tissue IL-33. Taken together, these data indicate that DerP1/2 is able to modify the allergic immune response, with higher levels inducing a suppression of allergic inflammation and achieving an enhanced lung function.
| DISCUSSION
In this study, we asked whether purified Der p1 and 2 would have 
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Another potential advantage of the use of purified proteins over an extract for SIT is the lack of nonprotein constituents of the extracts, including chitin, beta-glucans, and endotoxins. These contaminants might activate a pro-inflammatory innate response upon injection of the vaccine. We observe a reduction in HDM-induced CCL20 levels and a trend toward reduction in CCL11/eotaxin, CCL17/TARC, and IL-33 levels in DerP1/2-SCIT mice, which might reflect a reduced activation status of the innate immune system. In agreement herewith, it has been reported that full extract challenges in allergic asthma patients induced a stronger late allergic response compared to challenges with Der p1 and 2, while early responses were identical, which was attributed to nonprotein constituents of the HDM extract. 24 Pro-inflammatory activation of the antigen-presenting cell during SCIT might also negatively influence the induction of a tolerogenic T-cell response. 25 However, some studies have reported successful use of TLR agonists as adjuvants for allergen immunotherapy, including monophosphoryl lipid A 26 or bacterial DNA rich in CpG motifs, 27 indicating that activation of specific PRRs may in fact be beneficial in SIT. Notwithstanding, using biochemically and pharmacologically defined products for SIT will increase quality of the treatment. 30 Further research will need to establish whether purified natural allergens, that can be produced in relatively high quantities under strictly controlled conditions at relatively low costs and address both effector cell responses, B-cell and T-cell activity, or recombinant hypoallergenic or peptide vaccines that require far higher production costs and mainly address the Tcell response, will be the most optimal treatment for SIT.
We provide evidence that Der p1 and 2 can be used as a phar- 
